Glaukos price target raised to $90 from $85 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos to $90 from $85 and keeps an Overweight rating on the shares. The company reported Q2 results that beat expectations and raised its guidance, which reaffirmed the firm’s belief that guidance is conservatively set, the analyst tells investors. Further, Piper Sandler continues to believe Wall Street underappreciates the launches of Infinite and iDose and expect FY24 and FY25 numbers to increase compared to current estimates.